Access to health

The diabetes epidemic affects today close to 371 million people according to IDF. It is estimated that within twenty years it will reach 552 million people. Most of these will be in developing countries. This situation calls for a concerted action to improve access to diabetes care in developing countries.

As a world leader in diabetes care, Novo Nordisk wants to ensure that more people with diabetes in developing countries have access to healthcare. The Novo Nordisk strategy for access to diabetes care is founded on our company's vision to defeat diabetes. It aims to improve the conditions for the next generations by protecting the most vulnerable and building partnerships and capacity to confront the diabetes epidemic in least developed countries and emerging economies.

At the UN high-level meeting in New York in September 2011 our new approach to access to health was presented. Click for full version or the executive summary

For more information on our annual performance, see our Annual Report.

For more information about our latest activities, see our Reporting to UN Global Compact Communication on Progress.

For information about our programmes related to the access to health agenda, go to our website


In addition Novo Nordisk has created the following organisations:

World Diabetes Foundation
The WDF is dedicated to supporting the prevention and treatment of diabetes in the developing world through the funding of sustainable...
See our latest annual report
Visit WDF's website

Haemophilia Foundation
Novo Nordisk Haemophilia Foundation was created in 2005 to address the significant need for improving haemophilia care in the developing...
See our latest annual report
Visit NNHF's website